+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment
+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95 (2000) 3653-3661
+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49 (2003) 1049-1058
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders. A clinicopathologic study of 65 cases
Vergier B., Beylot-Barry M., Pulford K., Michel P., Bosq J., de Muret A., et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders. A clinicopathologic study of 65 cases. Am J Surg Pathol 22 (1998) 1192-1202
Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders
Vonderheid E.C., Sajjadian A., and Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34 (1996) 470-481
Treatment of keratoacanthomas with intralesional methotrexate
Melton J.L., Nelson B.R., Stough D.B., Brown M.D., Swanson N.A., and Johnson T.M. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol 25 (1991) 1017-1023